Clinical Trials Arena on MSN4d
BMS’ Phase II trial of CAR T cell therapy meets primary endpointBristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Hosted on MSN2mon
Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphomaIn the marginal zone lymphoma trial, 70% of patients had a complete response and 91% had an overall response. As this trial is still ongoing, Lossos is presenting interim results at the conference ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...
An expert has shared that excessive use of hot water bottles could not only burn the skin but increase your risk of a deadly ...
US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene ...
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...
Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback